Targeting a Poor Prognosis Marker for Tumor Therapy
Targeting a Poor Prognosis Marker for Tumor Therapy
批准号:
7999984
负责人:
Douglas A Lappi
金额:
$15.05万
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-07-01 至 2011-06-30
关键词:
AntibodiesBindingBinding ProteinsBoxingCD147 antigenCancer cell lineCause of DeathCell DeathCell ProliferationCell membraneCell surfaceCellsCollaborationsCytotoxinDataDisseminated Malignant NeoplasmDoseEndocytosisExperimental DesignsExtracellular DomainExtracellular MatrixFibroblast Growth FactorFibroblastsFlow CytometryGelatinase AGoalsGrantIllinoisIndividualInterstitial CollagenaseInterventionMalignant NeoplasmsMatrix MetalloproteinasesMedicalModelingMonoclonal AntibodiesMusNational Cancer InstituteNeoplasm MetastasisPharmaceutical PreparationsPhasePlayProcessPrognostic MarkerProtein BiosynthesisProtein Synthesis InhibitionProteinsRecombinantsResistanceRibosomesRoleSerum ProteinsSpecificityStreptavidinStromelysin 1SurfaceSurvival RateSystemTechnologyTissuesToxinUnited StatesUniversitiesVascular Endothelial CellWorkangiogenesisbasigin-2cancer typecytotoxicitydesigndrug developmentimprovedin vivoinnovationneoplastic celloutcome forecastpublic health relevanceresearch studyresponsetumortumor growth
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant):
Targeting a Poor Prognosis Marker for Tumor Therapy Summary The purpose of this proposal is to develop a medical treatment for the elimination of metastatic cancers. According to the National Cancer Institute, the survival rate for many types of cancer has improved in recent years; however, it is still the second leading cause of death in the United States. This proposal describes an experimental design to verify the suitability of basigin-2 (also known as CD147 or EMMPRIN) as a cell surface target for an innovative tumor therapy. This project will accomplish important goals in determining the suitability of basigin-2 for further drug development: 1) Provide proof of internalization of the target moiety (basigin-2) by using an antibody to basigin-2, and 2) Demonstrate that there is specificity, both in terms of greater ability to target the tumor over normal (lower level) expression and that anti-basigin is specific for the target. In this Phase I grant, a cytotoxin will be produced that has two components: 1) anti-basigin to specifically target and internalize into basigin-2 positive cells, and 2) a toxin that will inhibit protein synthesis upon internalization by the antibody. This innovative approach will create a molecule that targets tumor cells, metastasis and angiogenesis, with the idea to not just slow tumor cell proliferation, but to eliminate tumors.
PUBLIC HEALTH RELEVANCE:
Targeting a Poor Prognosis Marker for Tumor Therapy Narrative This project begins a new direction of potential treatment for a wide range of deadly cancers by targeting a molecule that is expressed on the surface of many tumor types with poor prognosis. While it is proposed to directly target these tumors through targeting the molecule, basigin-2, targeting of tumor metastasis and angiogenesis is also indicated, since basigin-2 plays important roles in those dangerous processes. The project builds on current technologies, but puts several together to go in a new, innovative direction.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Enhancing CRISPR-based Therapeutic Interventions Via a Targeted Platform Tool
-
批准号:9253170
-
项目类别:
-
资助金额:$15.0万
-
财政年份:2017
-
负责人:Douglas A Lappi
-
依托单位:
Development of a Novel Cancer Pain Therapeutic
-
批准号:7928286
-
项目类别:
-
资助金额:$300.0万
-
财政年份:2010
-
负责人:Douglas A Lappi
-
依托单位:
Selective Activation in Specific Neuronal Populations
-
批准号:7538504
-
项目类别:
-
资助金额:$9.92万
-
财政年份:2009
-
负责人:Douglas A Lappi
-
依托单位:
Inhibition of Neurotransmission in Specific Neuronal Populations
-
批准号:7482543
-
项目类别:
-
资助金额:$11.43万
-
财政年份:2008
-
负责人:Douglas A Lappi
-
依托单位:
Isolation of Pancreatic Islets by FACS
-
批准号:6443679
-
项目类别:
-
资助金额:$10.0万
-
财政年份:2002
-
负责人:Douglas A Lappi
-
依托单位:
Targeting Neurons Involved in Chronic Pain Transmission
-
批准号:6344012
-
项目类别:
-
资助金额:$13.35万
-
财政年份:2001
-
负责人:Douglas A Lappi
-
依托单位:
A TOOL TO STUDY THE DIVERSE BEHAVIOR EFFECTS OF GALANIN
-
批准号:6210155
-
项目类别:
-
资助金额:$10.0万
-
财政年份:2000
-
负责人:Douglas A Lappi
-
依托单位:
MAB'S TO TARGET SPECIFIC NEURONAL POPULATIONS
-
批准号:2873100
-
项目类别:
-
资助金额:$11.32万
-
财政年份:1999
-
负责人:Douglas A Lappi
-
依托单位:
TOOLS FOR THE DISSECTION OF PAIN TRANSMISSION PATHWAYS
-
批准号:6022028
-
项目类别:
-
资助金额:$10.0万
-
财政年份:1999
-
负责人:Douglas A Lappi
-
依托单位:
Monoclonal Antibodies to Target Neuronal Populations
-
批准号:6585715
-
项目类别:
-
资助金额:$34.13万
-
财政年份:1999
-
负责人:Douglas A Lappi
-
依托单位:
Monoclonal Antibodies to Target Neuronal Populations
-
批准号:6851809
-
项目类别:
-
资助金额:$17.49万
-
财政年份:1999
-
负责人:Douglas A Lappi
-
依托单位:
Monoclonal Antibodies to Target Neuronal Populations
-
批准号:6698825
-
项目类别:
-
资助金额:$28.22万
-
财政年份:1999
-
负责人:Douglas A Lappi
-
依托单位:
NEW TOOLS FOR BASIC NEUROBIOLOGICAL RESEARCH
-
批准号:6550417
-
项目类别:
-
资助金额:$27.61万
-
财政年份:1996
-
负责人:Douglas A Lappi
-
依托单位:
Drug Development of a Chronic Pain Therapeutic
-
批准号:6692707
-
项目类别:
-
资助金额:$79.97万
-
财政年份:1996
-
负责人:Douglas A Lappi
-
依托单位:
Drug Development of a Chronic Pain Therapeutic
-
批准号:6919960
-
项目类别:
-
资助金额:$78.92万
-
财政年份:1996
-
负责人:Douglas A Lappi
-
依托单位:
Drug Development of a Chronic Pain Therapeutic
-
批准号:6803957
-
项目类别:
-
资助金额:$80.0万
-
财政年份:1996
-
负责人:Douglas A Lappi
-
依托单位:
NEW TOOL FOR BASIC NEUROBIOLOGICAL RESEARCH
-
批准号:2035047
-
项目类别:
-
资助金额:$10.0万
-
财政年份:1996
-
负责人:Douglas A Lappi
-
依托单位:
NEW TOOLS FOR BASIC NEUROBIOLOGICAL RESEARCH
-
批准号:2650727
-
项目类别:
-
资助金额:$40.46万
-
财政年份:1996
-
负责人:Douglas A Lappi
-
依托单位:
TOXICOLOGY/SAFETY STUDIES OF A CHRONIC PAIN THERAPEUTIC
-
批准号:6292613
-
项目类别:
-
资助金额:$39.8万
-
财政年份:1996
-
负责人:Douglas A Lappi
-
依托单位:
NEW TOOLS FOR BASIC NEUROBIOLOGICAL RESEARCH
-
批准号:2890877
-
项目类别:
-
资助金额:$34.48万
-
财政年份:1996
-
负责人:Douglas A Lappi
-
依托单位:
国内基金
海外基金
登录
查看更多内容
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
-
批准号:32170319
-
项目类别:面上项目
-
资助金额:58.00万元
-
批准年份:2021
-
负责人:董春海
-
依托单位:
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
-
批准号:--
-
项目类别:--
-
资助金额:58万元
-
批准年份:2021
-
负责人:董春海
-
依托单位:
ID1 (Inhibitor of DNA binding 1) 在口蹄疫病毒感染中作用机制的研究
-
批准号:31672538
-
项目类别:面上项目
-
资助金额:62.0万元
-
批准年份:2016
-
负责人:孙跃峰
-
依托单位:
番茄EIN3-binding F-box蛋白2超表达诱导单性结实和果实成熟异常的机制研究
-
批准号:31372080
-
项目类别:面上项目
-
资助金额:80.0万元
-
批准年份:2013
-
负责人:杨迎伍
-
依托单位:
P53 binding protein 1 调控乳腺癌进展转移及化疗敏感性的机制研究
-
批准号:81172529
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2011
-
负责人:杨其峰
-
依托单位:
DBP(Vitamin D Binding Protein)在多发性硬化中的作用和相关机制的蛋白质组学研究
-
批准号:81070952
-
项目类别:面上项目
-
资助金额:35.0万元
-
批准年份:2010
-
负责人:刘师莲
-
依托单位:
研究EB1(End-Binding protein 1)的癌基因特性及作用机制
-
批准号:30672361
-
项目类别:面上项目
-
资助金额:24.0万元
-
批准年份:2006
-
负责人:徐宁志
-
依托单位: